

28 April 2026

Medicine supplied via Registered Homecare Services

Please provide information relating to medicines supplied via registered homecare companies for the most recent full financial year available

Please provide the top 10 drug molecules ranked by total expenditure (£) within this.

1. For each of these 10 molecules, please provide:
 - Total annual spend (£)
 - The highest average annual cost per patient
 - The lowest average annual cost per patient

Response:

1. Medicines supplied via registered homecare companies for financial year 1st April 2025 – 31st March 2026. The table below indicates the top 10 drug molecules, their total annual spend, ranked by total expenditure.

	Drug - Simple Generic Name	Approximate Value
1	adalimumab	£ 3,645,635.10
2	ofatumumab	£ 2,516,376.72
3	secukinumab	£ 2,149,091.11
4	immunoglobulin human normal	£ 1,964,475.22
5	etanercept	£ 1,923,498.82
6	abatacept	£ 1,877,303.24
7	dupilumab	£ 1,762,249.82
8	ravulizumab	£ 1,736,112.01
9	vedolizumab	£ 1,699,500.00
10	risankizumab	£ 1,599,015.00

2. The highest average annual cost per patient - we cannot give this information as may identify the PAS or contract price of the medicine

3. The lowest average annual cost per patient- we cannot give this information as may identify the PAS or contract price of the medicine